.avif)
Horizon Therapeutics Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Dublin, Ireland
Horizon Therapeutics is a biotechnology company that developed medicines for rare, autoimmune, and severe inflammatory diseases before being acquired by Amgen.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@horizontherapeutics.com
Company Overview
Industry
Biotechnology Research
Founded
2008
Headquarters
Dublin, Ireland
Revenue
$2.5B-$5B
FUNDING Stage
Acquired
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Horizon Therapeutics?
Horizon Therapeutics uses the firstinitiallast format, so Jane Smith would be jsmith@horizontherapeutics.com.
What are the three flagship rare disease medicines in the Horizon Therapeutics portfolio?
Horizon Therapeutics built its portfolio around three first-in-class rare disease medicines: Tepezza for thyroid eye disease, Krystexxa for refractory gout, and Uplizna for neuromyelitis optica spectrum disorder and IgG4-related disease.
How does Horizon Therapeutics operate as part of Amgen?
Horizon Therapeutics operates as a subsidiary of Amgen following the completion of Amgen's $27.8 billion acquisition in October 2023. The company retains its Dublin, Ireland registration and its U.S. operations in Deerfield, Illinois, with approximately 2,698 employees.
Can I use Clay to find and verify Horizon Therapeutics employee contact details?
Yes, Clay can help you look up and verify Horizon Therapeutics employee emails using the firstinitiallast format, cross-referencing LinkedIn and other data sources to confirm contacts before outreach or enriching a prospect list.
When did Horizon Therapeutics receive FDA approval for Tepezza as the first treatment for thyroid eye disease?
The FDA approved Horizon Therapeutics' Tepezza in January 2020, making it the first and only approved treatment for thyroid eye disease, a rare autoimmune condition that causes progressive, potentially vision-threatening inflammation behind the eyes.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating